Important Note: The information provided on any Fast Facts document is intended for use as a general eligibility checklist only. FAST FACTS ARE NOT TO BE USED AS TREATMENT SCHEMA. Contact GRCOP at (616) 391-1230 for specific patient eligibility requirements and the formal treatment plan.

Open Protocols

Brain/CNS

Cancer Type:	Germinoma
Research Base:	COG
Protocol:	ACNS0232
	Fast Facts

ACNS0232: Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma

Physician Summary: ≥ age 3 and ≤ age 30, Newly Dx: XRT vs Carboplatin + Etoposide f/b response based XRT + Chemo

Cancer Type:	Medulloblastoma PNET
Research Base:	COG
Protocol:	ACNS0332
	Fast Facts

COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Physician Summary:

≤ age 21; Newly Dx: RT+ Vincristine +/- Carboplatin f/b Maint +/- Continuous Isotretinoin

Cancer Type:	Neuroblastoma
Research Base:	COG
Protocol:	ANBL0532
	Fast Facts

COG-ANBL0532: Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma

Physician Summary: ≤ age 30: Single vs. Tandem Myeloblative as Consolidation Therapy

Cancer Type:	Re-current Glioblastoma
Research Base:	NCCTG
Protocol:	N0779
	Fast Facts

N0779: Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients with Recurrent Glioblastoma Multiforme

Physician Summary: ≥ age 18; Recurrent GBM: Vorinostat + Bortezomib w/ or w/out Surgery

Breast

Cancer Type:	Lymphedema Prevention
Research Base:	CALGB
Protocol:	70305
	Fast Facts

70305: A Randomized Study to Prevent Lymphedema in Women Treated For Breast Cancer

Physician Summary: Newly Diagnosed Stage I – IV: Study to Prevent Lymphedema

Cancer Type:	Neoadjuvant Breast
Research Base:	NSABP
Protocol:	B-41
	Fast Facts

NSABP B-41: A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC

Physician Summary: ≥ age 18; HER2+; Node +/-: AC f/b wkly Paclitaxel w/Herceptin +, Lapatinib or Herceptin + Lapatanib f/b surgery f/b Herceptin

Cancer Type:	Nausea/Breast Chemo pts.
Research Base:	URCC
Protocol:	U1105
	Fast Facts

URCC U1105: Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Physician Summary: ≥ age 18; Chemo Naïve receiving Doxorubicin or Epirubicin: Anti-emetic Therapy All Drugs Provided for 1 Cycle only

Cancer Type:	Breast/Observational Cohort
Research Base:	CALGB
Protocol:	369901
	Fast Facts

369901: Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older with Ope